Pluri Inc. (NASDAQ:PLUR) Sees Large Decline in Short Interest

Pluri Inc. (NASDAQ:PLUR) was the target of a significant drop in short interest in February. As of February 28th, there was short interest totalling 25,800 shares, a drop of 14.0% from the February 13th total of 30,000 shares. Currently, 0.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 12,700 shares, the days-to-cover ratio is currently 2.0 days.

Pluri Price Performance

NASDAQ:PLUR traded up $0.06 during mid-day trading on Thursday, reaching $4.55. 5,405 shares of the stock were exchanged, compared to its average volume of 18,050. The company has a current ratio of 5.04, a quick ratio of 5.04 and a debt-to-equity ratio of 4.44. The business has a fifty day moving average price of $4.46 and a 200 day moving average price of $4.81. Pluri has a 1-year low of $4.07 and a 1-year high of $8.40. The firm has a market capitalization of $31.84 million, a PE ratio of -0.81 and a beta of 1.76.

Pluri (NASDAQ:PLUR) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.53) earnings per share (EPS) for the quarter. Pluri had a negative return on equity of 2,778.13% and a negative net margin of 3,551.49%.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pluri stock. Renaissance Technologies LLC lifted its stake in shares of Pluri Inc. (NASDAQ:PLUR) by 38.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,025 shares of the company’s stock after acquiring an additional 9,400 shares during the quarter. Renaissance Technologies LLC owned 0.61% of Pluri worth $145,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 16.59% of the company’s stock.

About Pluri

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.